Stockholm - Delayed Quote SEK

Newbury Pharmaceuticals AB (publ) (NEWBRY.ST)

Compare
3.5200
+0.0200
+(0.57%)
At close: January 17 at 5:06:30 PM GMT+1
Loading Chart for NEWBRY.ST
DELL
  • Previous Close 3.5000
  • Open 3.5600
  • Bid 3.5000 x --
  • Ask 3.6400 x --
  • Day's Range 3.5000 - 3.5600
  • 52 Week Range 2.4000 - 6.2400
  • Volume 11,463
  • Avg. Volume 21,608
  • Market Cap (intraday) 85.391M
  • Beta (5Y Monthly) 1.46
  • PE Ratio (TTM) --
  • EPS (TTM) -0.6400
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 8.00

Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden and the Scandinavian market. The company offers oncology, rare diseases, neurology, and other treatment products. Newbury Pharmaceuticals AB (publ) was incorporated in 2020 and is based in Lund, Sweden.

www.newburypharma.com

6

Full Time Employees

August 31

Fiscal Year Ends

Recent News: NEWBRY.ST

View More

Performance Overview: NEWBRY.ST

Trailing total returns as of 1/17/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

NEWBRY.ST
0.00%
OMX Stockholm 30 Index
5.41%

1-Year Return

NEWBRY.ST
4.61%
OMX Stockholm 30 Index
12.64%

3-Year Return

NEWBRY.ST
74.31%
OMX Stockholm 30 Index
10.99%

5-Year Return

NEWBRY.ST
74.31%
OMX Stockholm 30 Index
44.42%

Compare To: NEWBRY.ST

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NEWBRY.ST

View More

Valuation Measures

Annual
As of 1/17/2025
  • Market Cap

    85.39M

  • Enterprise Value

    70.09M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.32

  • Price/Book (mrq)

    1.64

  • Enterprise Value/Revenue

    1.90

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -41.83%

  • Return on Assets (ttm)

    -12.96%

  • Return on Equity (ttm)

    -30.42%

  • Revenue (ttm)

    36.83M

  • Net Income Avi to Common (ttm)

    -15.4M

  • Diluted EPS (ttm)

    -0.6400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    15.3M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -5.03M

Research Analysis: NEWBRY.ST

View More

Company Insights: NEWBRY.ST

Research Reports: NEWBRY.ST

View More

People Also Watch